This company has been marked as potentially delisted and may not be actively trading. NASDAQ:APGE Apogee Therapeutics (APGE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsInsider TradesNews and TrendsOwnershipShort Interest About Apogee Therapeutics Stock (NASDAQ:APGE) Get Apogee Therapeutics alerts:Sign Up Key Stats Today's Range$135.07▼$135.0750-Day Range$134.09▼$135.1052-Week Range$35.39▼$135.09VolumeN/AAverage Volume1.39 million shsMarket Capitalization$8.40 billionP/E RatioN/ADividend YieldN/APrice Target$126.77Consensus RatingHold Company Overview Apogee Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologic medicines for inflammatory and immunologic diseases. The company’s approach emphasizes therapies designed to offer extended dosing intervals, with the goal of improving convenience and treatment options for patients with chronic conditions. Apogee’s lead program is APG777, a long-acting monoclonal antibody that targets interleukin-13 (IL-13), a cytokine involved in allergic inflammation. The program is being developed for conditions including atopic dermatitis, asthma and other inflammatory diseases. The company is also advancing APG808, an extended-half-life antibody targeting the interleukin-4 receptor alpha (IL-4Rα) pathway, which is implicated in several type 2 inflammatory disorders. Apogee was established in 2022 and became a publicly traded company on the Nasdaq under the symbol APGE in 2023. The company is headquartered in San Francisco, California, and its development activities are focused on addressing unmet needs in inflammatory and immunologic diseases. Apogee is led by Chief Executive Officer Michael Henderson.AI Generated. May Contain Errors. Read More Apogee Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScoreAPGE MarketRank™: 0.79400552123 of 5 starsApogee Therapeutics scored higher than 16% of companies evaluated by MarketBeat, and ranked 830th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingHold Consensus RatingApogee Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.16, and is based on 1 strong buy rating, 2 buy ratings, 15 hold ratings, and 1 sell rating.Downside RiskApogee Therapeutics has a consensus price target of $126.77, representing about 6.1% downside from its current price of $135.07.Amount of Analyst CoverageApogee Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Apogee Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Apogee Therapeutics are expected to decrease in the coming year, from ($4.47) to ($5.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apogee Therapeutics is -31.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apogee Therapeutics is -31.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApogee Therapeutics has a P/B Ratio of 7.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Apogee Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.93% of the float of Apogee Therapeutics has been sold short.Short Interest Ratio / Days to CoverApogee Therapeutics has a short interest ratio ("days to cover") of 3.47, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Apogee Therapeutics has recently decreased by 1.65%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldApogee Therapeutics does not currently pay a dividend.Dividend GrowthApogee Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Apogee Therapeutics this week, compared to 5 articles on an average week.Search Interest1 people have searched for APGE on MarketBeat in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Apogee Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $737,935.00 in company stock.Percentage Held by Insiders24.30% of the stock of Apogee Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.04% of the stock of Apogee Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Apogee Therapeutics' insider trading history. Receive APGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apogee Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APGE Stock News HeadlinesParagon Labs Adds Former Apogee Leaders As Alaunos Completes Velaris Acquisition; Stock UpOctober 13 at 2:33 PM | rttnews.comApogee Therapeutics Inc. (NASDAQ:APGE) Receives Consensus Recommendation of "Hold" from AnalystsOctober 4, 2026 | americanbankingnews.comHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling shares or trading options, but simply by holding the fund and letting it pay out cash every Thursday. That works out to a 34% annualized distribution rate, even though the underlying AI stocks pay no dividends themselves. Tim Plaehn, Chief Income Strategist at Investors Alley, breaks down exactly how the fund generates these weekly payouts.October 14 at 1:00 AM | Investors Alley (Ad)Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from S&P Global BMI IndexSeptember 3, 2026 | marketscreener.comMAbbVie Closes $10.9 Billion Acquisition of Apogee TherapeuticsSeptember 3, 2026 | finance.yahoo.comApogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from S&P Biotechnology Select Industry IndexSeptember 3, 2026 | marketscreener.comMAbbVie Completes $10.9 Bln Acquisition Of Apogee TherapeuticsSeptember 3, 2026 | rttnews.comAbbVie seals $11B acquisition of Apogee TherapeuticsSeptember 3, 2026 | msn.comSee More Headlines APGE Stock Analysis - Frequently Asked Questions How were Apogee Therapeutics' earnings last quarter? Apogee Therapeutics Inc. (NASDAQ:APGE) posted its quarterly earnings data on Monday, August, 10th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($1.07) by $0.07. When did Apogee Therapeutics IPO? Apogee Therapeutics (APGE) raised $282 million in an initial public offering on Thursday, July 13th 2023. The company issued 17,650,000 shares at a price of $15.00-$17.00 per share. What other stocks do shareholders of Apogee Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apogee Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Atai Beckley (ATAI), BridgeBio Pharma (BBIO), Corbus Pharmaceuticals (CRBP), DraftKings (DKNG) and Exelixis (EXEL). Company Calendar Last Earnings8/10/2026Today10/14/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 APGE's financial health is in the Green zone, according to TradeSmith. APGE has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:APGE CIK1974640 Webwww.apogeetherapeutics.com Phone650-394-5230FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Price Target for Apogee Therapeutics$126.77 High Price Target$160.00 Low Price Target$89.00 Potential Upside/Downside-6.1%Consensus RatingHold Rating Score (0-4)2.16 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)($4.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$255.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-29.88% Return on Assets-28.08% Debt Debt-to-Equity RatioN/A Current Ratio26.44 Quick Ratio26.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$19.21 per share Price / Book7.03Miscellaneous Outstanding Shares62,201,000Free Float47,086,000Market Cap$8.40 billion OptionableOptionable Beta0.33 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:APGE) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APGE Stock Alerts